Add to ORKGThe scientific documentation supporting the potential clinical and economic benefits of a growing use of off-patent generic drugs in clinical practice seems to be limited in Italy as yet. Methods: We compared differences in outcomes between off-patent generic drugs and off-patent brand drugs in real clinical practice. The outcomes were: persistence and compliance with therapy, mortality, and other health resources consumption (hospitalizations, specialist examinations, other drugs) and total costs. Retrospective analysis was carried out by using the administrative databases of five Local Healthcare Units (ASLs- Aziende Sanitarie Locali) in the Lombardy Region of Italy. Data from the five ASLs were aggregated through a meta-analysis, which p...
BackgroundTo the extent that outcomes are mediated through negative perceptions of generics (the noc...
Background: Use of generic drugs can help contain drug spending. However, there is concern among pat...
The generic reference price system (RPS) can impose a financial penalty for patients using a brand n...
The scientific documentation supporting the potential clinical and economic benefits of a growing us...
The scientific documentation supporting the potential clinical and economic benefits of a growing us...
INTRODUCTION: The appearance of off-patent generic drugs in the world pharmaceutical market is a h...
Purpose: To assess patterns of use of antiseizure medications (ASMs) and to compare the safety of ge...
Objectives: The generic reference price (GRP) was introduced in Italy in 2001. The main purpose of t...
The new Italian policy to off-patent prod ucts, although similar to recent reforms in other Europe...
Although generic medicines can be beneficial to patients and the healthcare system thanks to the con...
Prescription of generic medicines represents an efficacious healthcare cost containment strategy. In...
Italy is among the European countries with the lowest uptake of generic medicines. This paper provid...
A generic medicine is a faithful copy of a mature drug - no longer under patent - marketed with the ...
We study the evolution of statin consumption between 2005-2017 in the Italian region Emilia-Romagna....
BackgroundTo the extent that outcomes are mediated through negative perceptions of generics (the noc...
BackgroundTo the extent that outcomes are mediated through negative perceptions of generics (the noc...
Background: Use of generic drugs can help contain drug spending. However, there is concern among pat...
The generic reference price system (RPS) can impose a financial penalty for patients using a brand n...
The scientific documentation supporting the potential clinical and economic benefits of a growing us...
The scientific documentation supporting the potential clinical and economic benefits of a growing us...
INTRODUCTION: The appearance of off-patent generic drugs in the world pharmaceutical market is a h...
Purpose: To assess patterns of use of antiseizure medications (ASMs) and to compare the safety of ge...
Objectives: The generic reference price (GRP) was introduced in Italy in 2001. The main purpose of t...
The new Italian policy to off-patent prod ucts, although similar to recent reforms in other Europe...
Although generic medicines can be beneficial to patients and the healthcare system thanks to the con...
Prescription of generic medicines represents an efficacious healthcare cost containment strategy. In...
Italy is among the European countries with the lowest uptake of generic medicines. This paper provid...
A generic medicine is a faithful copy of a mature drug - no longer under patent - marketed with the ...
We study the evolution of statin consumption between 2005-2017 in the Italian region Emilia-Romagna....
BackgroundTo the extent that outcomes are mediated through negative perceptions of generics (the noc...
BackgroundTo the extent that outcomes are mediated through negative perceptions of generics (the noc...
Background: Use of generic drugs can help contain drug spending. However, there is concern among pat...
The generic reference price system (RPS) can impose a financial penalty for patients using a brand n...